PTIX Key Statistics, Chart & Performance
The current stock price of PTIX is 2.36 USD. In the past month the price decreased by -19.2%. In the past year, price decreased by -73%.
PTIX Latest News, Press Relases and Analysis
PTIX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.17 | 403.50B | ||
| AMGN | AMGEN INC | 15.62 | 183.87B | ||
| GILD | GILEAD SCIENCES INC | 15.51 | 157.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.72 | 110.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.45 | 83.24B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.79 | 57.75B | ||
| INSM | INSMED INC | N/A | 43.62B | ||
| NTRA | NATERA INC | N/A | 32.78B | ||
| BIIB | BIOGEN INC | 10.91 | 26.78B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.38 | 21.94B | ||
| INCY | INCYTE CORP | 16.45 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About PTIX
Company Profile
Protagenic Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The firm has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The firm's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The firm's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The firm's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
Company Info
PROTAGENIC THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK 10010 US
CEO: Garo H. Armen
Employees: 2
Phone: 12129948200
PROTAGENIC THERAPEUTICS INC / PTIX FAQ
What does PROTAGENIC THERAPEUTICS INC do?
Protagenic Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The firm has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The firm's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The firm's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The firm's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
What is the current price of PTIX stock?
The current stock price of PTIX is 2.36 USD. The price increased by 5.83% in the last trading session.
Does PTIX stock pay dividends?
PTIX does not pay a dividend.
What is the ChartMill technical and fundamental rating of PTIX stock?
PTIX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for PTIX stock?
PROTAGENIC THERAPEUTICS INC (PTIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.61).
What is PROTAGENIC THERAPEUTICS INC worth?
PROTAGENIC THERAPEUTICS INC (PTIX) has a market capitalization of 4.55M USD. This makes PTIX a Nano Cap stock.
PTIX Technical Analysis
PTIX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PTIX. PTIX has a bad profitability rating. Also its financial health evaluation is rather negative.
PTIX Financial Highlights
Over the last trailing twelve months PTIX reported a non-GAAP Earnings per Share(EPS) of -9.61. The EPS increased by 52.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -133.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |